ABSTRACT - 603802 The disclosure relates to 2-{ 5-Chloro-2-[(1R,2R)-2-hydroxycyclopentylamino]pyrimidin-4-yl} -N-cyclopropyl-1H-indole-4-carboxamide and 2-{ 5-Chloro-2-[(1R,2S)-2-hydroxycyclopentylamino]pyrimidin-4-yl} -N-cyclopropyl-1H-indole-4-carboxamide represented by the formula shown herein, which are potent IkappaB kinase-beta (IKK() inhibitors and are useful for treatment of cancer selected from the group consisting of multiple myeloma, colon cancer, large cell lung cancer, glioblastoma, pancreatic cancer, and ovarian cancer or for treating inflammatory diseases selected from the group consisting of rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, multiple sclerosis, and inflammatory bowel disease.
